Inflazome Announces Acquisition by Roche
21.9.2020 09:00:00 EEST | Business Wire | Press release
Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.
Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors.
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.
Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”
Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors. The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”
Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome.
About Inflazome
Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome has a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes.
Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.
Inflazome is headquartered in Dublin, Ireland.
About the NLRP3 Inflammasome
Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/
Contact information
Inflazome
Dr Jeremy Skillington | VP Business Development
E: j.skillington@inflazome.com
Media:
FTI Consulting
UK & International | Ciara Martin/Tim Stamper
T: +44 20 37271000
Ireland & International | Jonathan Neilan/Patrick Berkery
T: +353 86 602 5988
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 11:00:00 EEST | Press release
The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead the “AI Sovereignty – Possibility or Pipe Dream for Europe?” panel, debating whether Europe can realistically compete in the glob
MOVIVA ® launch spotlight at ESGE Days 20267.5.2026 10:58:00 EEST | Press release
During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.” Marcus Felstead, Chief Comm
Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 10:57:00 EEST | Press release
Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of the main conference program, Peter Templeton, President and CEO of USGBC and GBCI will present the GBCI Europe Impact Report 2026, ba
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom